Nevocentric erythema multiforme after SARS-COV-2 vaccine

A 27-year-old woman presented to our Dermatology Unit referring an acute skin rash with no associated systemic symptoms. Three days before, the patient had taken the SARS-COV-2 vaccine (Comirnaty™ – BioNTech/Pfizer - Mainz, Germany/New York, NY, USA). Physical examination showed erythematous, ring-shaped plaques only surrounding several, but not all of her melanocytic nevi (Fig. 1a–d). Dermoscopy revealed typical melanocytic nevi having a reticular or globular pigment pattern, surrounded by a purpuric red ring (Fig. 2a,b). A

Figure 1  Clinical images of nevocentric erythema multiforme presenting on arms (a and b), hands (c) and tights (d). Nevi of the back were not affected.
clinical diagnosis of a nevocentric erythema multiforme (EM) was made. Therapy with cetirizine 10 mg and moisturizers was initiated with complete resolution seen after 2 weeks. At the follow-up examination, no changes were found in her otherwise banal pre-existing nevi.

Most cases of nevocentric EM reported in the literature were described as a postherpetic phenomenon. McKenna and Pariser reported two adult female patients with nevocentric EM affecting the trunk and limbs after a HSV infection of the lower lip. Monsalvez et al. described the case of a pregnant woman, with history of recurrent labial herpes, presenting with halos of erythema around her nevi. Finally, Di Brizzi et al. reported a case of a 9-year-old girl presenting a nevocentric EM after labial herpes. The only case non-related to a herpetic infection was described by Humphreys and Cox occurring in a 37-year-old female patient after the ingestion of thiabendazole.

The reaction itself differs from the well-known phenomenon described by Meyerson in 1971, which consists of an eczematous halo surrounding a pre-existing melanocytic nevus, but it is not clear whether an interaction between CD4 T lymphocytes and increased expression of intercellular cell adhesion molecule 1 might be involved in both these nevocentric processes.

The course of nevocentric EM does not differ from the classical form of EM, and no alterations of the affected nevi were reported previously. Along these lines, patients can be reassured of the benign outcome of this condition.

Albeit the pathogenesis of EM ‘targeting’ nevi is obscure, in our case, we can hypothesize a similar mechanism as that involved in post-HSV nevocentric EM. The specific vaccine used in our patient was a modified messenger RNA in lipidic nanoparticles that allows the liberation of a non-replicant RNA inside the host cells, expressing the ‘S’ SARS-COV-2 antigen transitorily. It is therefore plausible that the vaccine may induce a similar reaction to that occurring after an HSV infection.

In conclusion, nevocentric EM is a benign, limited condition that can be added to the list of possible skin reactions associated with SARS-COV-2 vaccines.

**Acknowledgment**

The patient in this manuscript has given written informed consent to the publication of her case details.

**Funding source**

None.

**Conflict of interest**

None.

**Data availability statement**

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

C. Scharf, E.V. Di Brizzi, S. Pellerone, M. Liguori, C.M.R. Giorgio, G. Argenziano
Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
*Correspondence: C. Scharf. E-mail: kmischarf@gmail.com

**References**

1. Di Brizzi EV, Tartari F, Filippi F, Virdì A, Gurioli C, Neri I. Nevocentric erythema multiforme in a child. Pediatr Dermatol 2021; 38: 514–515. https://doi.org/10.1111/pde.14504. Epub 2020 Dec 29. PMID: 33372323.
2. Mc Kenna KE. Nevocentric erythema multiforme associated with herpes labialis. Br J Dermatol 1999; 141: 954–955.
3. Pariser RJ. Nevocentric erythema multiforme. J Am Acad Dermatol 1994; 31(3 pt 1): 491–492.
Dear Editor,

A 46-year-old female presented with a 1-week history of multiple erythema and blisters with pruritus on the extremities. She had received both doses of the SARS-CoV-2 vaccine (Corona Vac developed by Sinovac Life Sciences, Beijing, China), which is an inactivated vaccine. She had no adverse reactions after the first dose. The cutaneous lesions started 4 days after the second dose. She denied systemic diseases, medication history and medicine or food allergic history. Physical examination showed multiple circular erythema and blisters with classic target lesions on the distal extremities (Fig. 1). Multiple erosions involved her lip and oral mucosa (Fig. 2). Laboratory tests including blood routine, hepatic and renal function, T. pallidum particle assay, and HIV antibody serology test were normal or negative. The patient was diagnosed with erythema multiforme (EM) and treated with oral loratadine, rinsing with compound chlorhexidine gargle, and topical corticosteroids. The lesions and symptoms were completely relieved after 2 weeks. 

Erythema multiforme is an acute self-limited immune-mediated mucocutaneous disorder, and occasionally occurs with visceral involvement in severe patients. The lesions are distributed preferentially on the distal extremities with classic target lesions and may accompany a mucosal injury. Potential triggering factors of EM include infections (especially herpes simplex virus infections), drugs (containing vaccine), topical agents, and some systemic diseases.

With the worldwide vaccination campaign against the COVID-19 pandemic continuing, increasing cutaneous reactions after the SARS-CoV-2 vaccine have been reported. The most common reported cutaneous reactions included urticaria, local injection-site reaction and morbilliform rash. Other cutaneous reactions included delayed large local reaction, swelling, erythema, painful/itchy sensation, erythromelalgia, a flare of an existing dermatologic condition, vesicular, chilblains, zoster, angioedema, pityriasis rosea, filler reaction, vasculitis, contact dermatitis, rash in a breastfed infant, petechiae, lichen planus and EM. These reported cutaneous reactions were mainly associated with mRNA SARS-CoV-2 vaccine. There are few cutaneous reactions reported about inactivated SARS-CoV-2 vaccine in the literature.

In conclusion, cutaneous adverse reactions from the SARS-CoV-2 vaccine were very rare, mild and generally rapid spontaneous resolution. We should advance notice and reassure the vaccinator. Nevertheless, these adverse events and others should not discourage vaccination against a life-threatening virus.

Acknowledgements

The patients in this manuscript have given written informed consent to the publication of their case details. This content has not been published, nor has it been submitted for publication elsewhere. On behalf of all the contributors, Tao Chen will act as guarantor and will correspond with the journal from this point